An Observational Study of Patients With Coronavirus Disease 2019
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Target PharmaSolutions, Inc.
- Enrollment
- 199
- Locations
- 1
- Primary Endpoint
- Time point of clinical response
Study Overview
Brief Summary
This is an observational study of patients with COVID-19 designed to specifically address important clinical questions that remain incompletely answered for coronavirus disease 2019.
Detailed Description
Data from up to 5,000 adult patients in the US will be captured from eligible patients enrolled following admission to the hospital. Participants will have de-identified medical records collected from hospital admission to discharge, including but not limited to critical care monitoring, details on mechanical ventilation, laboratory data, imaging reports, medications, and all procedures. Diagnosis and patient management will follow each hospital's standard of care and no specific treatments, procedures or laboratory tests will be dictated by enrollment in TARGET-COVID-19.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adults (age ≥18 years) who are or have been hospitalized and diagnosed with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection.
- •SARS-CoV-2 confirmed diagnosis (e.g. polymerase chain reaction [PCR] or other clinically utilized test).
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Time point of clinical response
Time Frame: 12 months
Natural history of COVID-19: Characteristics of COVID-19
Time Frame: 12 months
Natural history of COVID-19: Participant demographics
Time Frame: 12 months
Natural history of COVID-19: Treatment use
Time Frame: 12 months
Secondary Outcomes
No secondary outcomes reported